Neurotrope Financial Statements (NTRP)
|
|
|
|
Report date
|
|
|
31.12.2020 |
31.12.2021 |
31.12.2022 |
29.02.2024 |
29.05.2025 |
|
14.01.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.807 |
1.65 |
0.630 |
|
0.501 |
|
2.18 |
|
Operating Income, bln rub |
|
|
-5.70 |
-8.48 |
-8.75 |
|
-8.41 |
|
-13.1 |
|
EBITDA, bln rub |
? |
|
-5.08 |
-7.28 |
-8.57 |
|
-7.70 |
|
-11.0 |
|
Net profit, bln rub |
? |
|
-5.20 |
-7.38 |
-8.69 |
|
-10.1 |
|
-15.2 |
|
|
OCF, bln rub |
? |
|
-4.81 |
-6.30 |
-8.21 |
-5.73 |
-5.08 |
|
-4.40 |
|
CAPEX, bln rub |
? |
|
0.299 |
0.360 |
0.389 |
1.03 |
0.535 |
|
0.448 |
|
FCF, bln rub |
? |
|
-5.11 |
-6.66 |
-8.60 |
-6.76 |
-5.61 |
|
-4.24 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
|
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
2.59 |
4.12 |
3.38 |
|
8.42 |
|
12.7 |
|
Cost of production, bln rub |
|
|
3.92 |
6.01 |
6.00 |
|
0.498 |
|
2.66 |
|
R&D, bln rub |
|
|
0.351 |
0.891 |
0.653 |
|
0.843 |
|
0.000 |
|
Interest expenses, bln rub |
|
|
0.014 |
0.011 |
0.007 |
|
0.000 |
|
1.17 |
|
|
Assets, bln rub |
|
|
5.70 |
13.8 |
5.70 |
5.09 |
9.94 |
|
14.4 |
|
Net Assets, bln rub |
? |
|
5.16 |
12.9 |
5.07 |
3.13 |
7.37 |
|
6.28 |
|
Debt, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.828 |
0.568 |
|
4.10 |
|
Cash, bln rub |
|
|
3.70 |
11.4 |
2.85 |
0.324 |
1.06 |
|
2.43 |
|
Net debt, bln rub |
|
|
-3.70 |
-11.4 |
-2.85 |
0.50 |
-0.49 |
|
1.67 |
|
|
Ordinary share price, rub |
|
|
67.6 |
36.8 |
8.00 |
2.99 |
3.98 |
|
2.58 |
|
Number of ordinary shares, mln |
|
|
0.191 |
0.491 |
0.525 |
|
4.57 |
|
8.97 |
|
|
Market cap, bln rub |
|
|
13 |
18 |
4 |
0 |
18 |
|
23 |
|
EV, bln rub |
? |
|
9 |
7 |
1 |
1 |
18 |
|
25 |
|
Book value, bln rub |
|
|
4 |
12 |
4 |
0 |
4 |
|
-1 |
|
|
EPS, rub |
? |
|
-27.2 |
-15.0 |
-16.6 |
|
-2.22 |
|
-1.70 |
|
FCF/share, rub |
|
|
-26.7 |
-13.5 |
-16.4 |
|
-1.23 |
|
-0.47 |
|
BV/share, rub |
|
|
23.0 |
24.3 |
7.52 |
|
0.89 |
|
-0.07 |
|
|
EBITDA margin, % |
? |
|
-629.2% |
-440.7% |
-1 359% |
|
-1 536% |
|
-506.4% |
|
Net margin, % |
? |
|
-644.0% |
-447.1% |
-1 379% |
|
-2 018% |
|
-698.5% |
|
FCF yield, % |
? |
|
-39.5% |
-36.8% |
-204.8% |
0.00% |
-30.9% |
|
-18.3% |
|
ROE, % |
? |
|
-100.7% |
-57.4% |
-171.3% |
0.00% |
-137.4% |
|
-242.7% |
|
ROA, % |
? |
|
-91.2% |
-53.4% |
-152.4% |
0.00% |
-101.9% |
|
-105.6% |
|
|
P/E |
? |
|
-2.49 |
-2.45 |
-0.48 |
|
-1.80 |
|
-1.52 |
|
P/FCF |
|
|
-2.53 |
-2.72 |
-0.49 |
0.00 |
-3.24 |
|
-5.45 |
|
P/S |
? |
|
16.0 |
10.9 |
6.66 |
|
36.2 |
|
10.6 |
|
P/BV |
? |
|
2.93 |
1.52 |
1.06 |
0.00 |
4.47 |
|
-35.2 |
|
EV/EBITDA |
? |
|
-1.82 |
-0.91 |
-0.16 |
|
-2.30 |
|
-2.25 |
|
Debt/EBITDA |
|
|
0.73 |
1.57 |
0.33 |
|
0.06 |
|
-0.15 |
|
|
R&D/CAPEX, % |
|
|
117.6% |
247.5% |
167.9% |
0.00% |
157.7% |
|
0 |
|
|
CAPEX/Revenue, % |
|
|
37.0% |
21.8% |
61.7% |
|
106.6% |
|
20.5% |
|
| Neurotrope shareholders |
